In the study AmphinexTM will beused in combination with the cytotoxic agent Bleomycin. The firstpatient is expected to be enrolled in September.Per Walday, CEO, said: "This is an important milestone in thedevelopment of Amphinex. Our preclinical results with Amphinex arevery encouraging and we are pleased to have been given the go-aheadby the Medicines Agency to start the clinical development of our leadproduct."
For more information, contact PCI Biotech:Per Walday (CEO) or Christian Fekete (CFO)Per Walday (pw@pcibiotech.no), Phone +47 91 79 34 29Christian Fekete (cf@photocure.no), Phone +47 91 64 29 38About PCI Biotech:PCI Biotech Holding ASA is a Norwegian company listed on Oslo Axesswith the mission to develop and commercialise a unique and patentedphotochemical drug delivery technology. PCI Biotech has developedand patented a novel photosensitiser, AmphinexTM, that is designed toenable light-directed delivery of therapeutic drugs in the bodythrough triggered endosomal release. The technology increases theintracellular availability of biologically active drugs and canenhance and target the effect of existing and new drugs on thediseased cells.
